Fertin Pharma

Business-oriented and proactive patent strategy ensures Fertin Pharma a stronger market position.

Fertin Pharma’s proactive, business-oriented, and intelligent patent strategy is an important element in the company’s efforts to develop and produce dietary supplements and pharmaceutical products that support a healthier living.

Fertin Pharma er verdens største business-to-business fremstiller af nikotintyggegummi til det globale marked og producerer produkter for flere af de største medicinalproducenter i verden. I de senere år har Fertin Pharma spredt deres aktiviteter og for eksempel etableret samarbejde med en førende medicinalproducent om nye, innovative tabletter til det amerikanske marked, der blandt andet har afstedkommet udvidelse af produktionsfaciliteterne i Vejle med en helt ny fabrik.

- One of the major breakthroughs in the field of IPR was the grant of two United States patents on a promising new technology under the name of Zapliq®, says Jesper Neergaard, Head of IPR at Fertin Pharma A/S. He collaborated with Kanved Patent Consulting and European Patent Attorney, Nicolai Kanved, on the patent strategy for the new technology.

- The technology is based on a new way of delivering active ingredients in tablets and is predicted a great future in terms of convenience and delivery of active ingredients. As a result of a unique composition of ingredients, the product works by melting very quickly and efficiently after oral administration and stimulating saliva. Several major consumer studies support consumers’ preference for the product, which is important vis-à-vis Fertin Pharma’s future positioning as a leader in our sector, explains Jesper Neergaard.

- Nicolai Kanved possesses the necessary professional skills, professional experience, and a strong commercial understanding. This combination gives him a profound basis for advising on how we best can protect a technology like Zapliq®, ensuring that we can maintain and strengthen our market position in an international, highly competitive market, says Jesper Neergaard, stressing the importance of strategic patent work when it comes to Fertin Pharma’s success in the market for pharmaceutical products.

Jesper Neergaard, Head of IPR at Fertin Pharma A/S

Well-planned patent strategy ensures broad protection

The patent strategy for Zapliq® resulted in the simultaneous filing of several patent applications, covering various aspects of the technology. The patent applications were filed directly in the United States, which accounts for the majority of Fertin Pharma’s sales, and as international patent applications (so-called PCT applications), which now, after approximately 30 months, have been filed nationally in most of the world.

- The strategy enables us to exert optimum control on the patenting process, spread the risk in terms of patent allowance and increase the likelihood of the broadest possible protection of the product, says the Head of IPR. He welcomes the close collaboration with Kanved Patent Consulting in all aspects of the patent work - from developing patent strategies to filing and prosecution of patent applications in countries such as China, the United States, Japan, India, Brazil, Australia and of course Europe.

- Nicolai Kanved possesses the necessary professional skills, professional experience, and a strong commercial understanding. This combination gives him a profound basis for advising on how we best can protect a technology like Zapliq®, ensuring that we can maintain and strengthen our market position in an international, highly competitive market, says Jesper Neergaard, stressing the importance of strategic patent work when it comes to Fertin Pharma’s success in the market for pharmaceutical products.

- It is business-to-business customers who market our products, and they are only interested if we have patent protection. Of course, they want to be certain that other companies cannot just copy a product and sell it, explains Jesper Neergaard, who welcomes the ongoing results in the collaboration with Kanved Patent Consulting for the world-leading, dietary supplement and pharmaceutical product company.

- Nicolai is good at integrating the various applications within the same field (for example, Zapliq) and to execute. He has a good overview of all our cases on the Zapliq technology and ensures that we will have patents issued, Jesper Neergaard emphasises.

Why did Fertin Pharma choose us?

Head of IPR, Jesper Neergaard, explains why he and Fertin Pharma A/S enjoy a long-term, strategic collaboration with Kanved Patent Consulting.

  1. Nicolai has a good understanding of the technology in a commercial perspective
  2. Experience with broad issued patents in the United States and Europe
  3. He is good at finding a path in the patent landscape and to execute
  4. We have an agile, flexible partner
  5. Nicolai has an overview of all our cases on the Zapliq technology
  6. He closely follows the development of patent legislation

What tasks do we perform?

Kanved Patent Consulting helps Fertin Pharma with:

  • Advice on patent strategies
  • Freedom to operate analyzes
  • Comprehensive disclosure of patent applications
  • Patent application filings and prosecution
  • Monitoring of patents and competitors in international databases
  • Patent infringement, invalidity cases and patent opposition cases

Fertin Pharma A/S - Facts

Fertin Pharma A/S helps leading global brands to create pharmaceutical and nutraceutical products that support a healthier living. They develop and manufacture innovative oral and intra-oral delivery systems that improve the efficiency of active and functional ingredients, without compromising on taste masking, texture and consumer experience.

With more than 800 employees in their research centres, development centres and production facilities in Canada, Denmark and India, they produce approximately 3 billion units per year, which are used by consumers at over the world.

In January 2017, Fertin Pharma A/S was acquired by EQT Mid Market. The founders, the Bagger-Sørensen family, have retained 30% of the shares in the company.

Read more about Fertin Pharma and Zapliq.

Contact

Nicolai Kanved

European Patent Attorney

Share:

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

Contact us

Receive a call

This website uses cookies. You accept this by clicking OK or by navigating further on the website.